EN DE
Watch Rossari Biotech Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rossari Biotech Limited (ROSSARI) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Rossari Biotech Limited stock ₹458, price ₹427, upside +7.2%, quality 45 out of 100. Rating: fairly valued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials IN · ISIN INE02A801020

RB Rossari Biotech Limited logo Broad data Nov 14, 2026

Rossari Biotech Limited

ROSSARI · NSE

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Ranks above peers (9/13) 
Broad data 
Revenue last quarter +19% vs. a year ago. 
Fair value ₹457.92 · Fairly valued 
Quality 45/100 
Expensive Growth (revenue 5y +27.6 %/yr in INR) 
Thin margins · 5.7% net margin (TTM) 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 43/100 · thin data
⟳ Cyclical
Watch Rossari Biotech Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,250 ₹378.60 Fair Value ₹457.92 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range ₹378.60 – ₹1,250 · fair‑value band ₹343.44 – ₹572.40 · the ₹427.15 price screens below the ₹457.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Rossari Biotech in your weekly email

Every Wednesday you see whether Rossari Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions.

Show moreShow less

The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names.

In addition, it offers poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations.

The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 1997 and is based in Mumbai, India.

Stock analysis

Rossari Biotech Limited (ROSSARI) currently trades at ₹427.15, while our model-based Fair Value estimate is ₹457.92, so the stock looks roughly fairly valued today (gap 6.7%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹735.13 per share, and 9 of the 16 models we run sit above the ₹427.15 price.

Bear case: the Asset-Based group reads lowest at ₹50.63, and 7 of the 16 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹343.44 (bear) to ₹572.40 (bull), the price of ₹427.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Basic Materials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Rossari Biotech Limited reported revenue of ₹24.0B in FY2026 versus ₹14.8B in FY2022, a compound +12.7%/yr. Reported net income was ₹1.5B in FY2026, compounding +11.2%/yr from FY2022.

Key figures

Market cap ₹23.7B (≈ $252M) Micro · P/E ratio 15.5 · P/S ratio 0.89 · EPS (TTM) ₹27.56 · Dividend yield 0.1% · Net margin 5.7% · Return on equity 11.5% · Return on assets (EBIT) 14.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at 7%, ROSSARI screens cheaper than that median.

Fair Value models

Bear ₹343.44 Fair Value ₹457.92 Bull ₹572.40
Price ₹427.15 · Upside +7.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹17.44 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹186.43 ₹198.25 ₹228.46 76
EPV ₹180.12 ₹199.66 ₹215.23 74
ROIC Compounder ₹180.12 ₹199.66 ₹215.23 72
All 16 models by family
Earnings-Based
Graham-Dodd ₹183.17 ₹1,277 ₹1,793 63
Lynch FV ₹423.36 ₹604.80 ₹786.24 61
PEG = 1.0 ₹423.36 ₹604.80 ₹786.24 57
EPV ₹180.12 ₹199.66 ₹215.23 74
Dividend Discount
Gordon GGM ₹3.18 ₹5.07 ₹6.34 69
DDM Multi-Stage ₹3.18 ₹4.93 ₹5.48 67
Multiples
P/E Multiple ₹343.44 ₹457.92 ₹572.40 63
P/S Multiple ₹343.44 ₹457.92 ₹572.40 58
P/B Multiple ₹450.63 ₹600.84 ₹751.05 55
EV/EBIT ₹329.90 ₹460.55 ₹591.20 66
EV/EBITDA ₹325.04 ₹454.07 ₹583.11 67
EV/Revenue ₹277.64 ₹423.22 ₹568.80 53
Asset-Based
NCAV (Graham) ₹33.42 ₹50.63 ₹63.29 54
Economic Profit
Residual Income ₹186.43 ₹198.25 ₹228.46 76
ROIC Compounder ₹180.12 ₹199.66 ₹215.23 72
Growth Earnings
Growth-Adj P/E ₹514.59 ₹735.13 ₹955.66 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 30
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.6%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.4%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+11.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.7%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.7% vs 24.7%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 9%
Pace: the 5-year rate starts in 2021 (pandemic)

Watch ROSSARI, get fair value alerts →

Compare Rossari Biotech Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 756 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside +7.2% · Above median
Profitability
Return on equity (12 months) 11.5% · Above median
Return on assets 6.5% · Above median
Net margin (12 months) 5.7% · Above median
Operating margin (12 months) 8.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 19.0% · Above median
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (12 months) 15.5× · Cheaper than median
P/B 1.78× · Pricier than median
P/S (12 months) 0.89× · Cheaper than median
EV/EBITDA 8.2× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)43 · sector 6
FUTURE (revenue growth)95 · sector 69
PAST (return on equity)46 · sector 26
HEALTH (low debt)96 · sector 95
DIVIDEND (yield)2 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wanhua Chemical Group 600309 ¥69.50 ¥68.03 −2% vs ROSSARI
Linde plc LIN $523.46 $446.62 −15% vs ROSSARI
PPG Industries, Inc PPG $121.97 $77.68 −36% vs ROSSARI
DSM-Firmenich AG DSFIR CHF 96.60 CHF 58.32 −40% vs ROSSARI
Asian Paints Limited ASIANPAINT ₹2,573 ₹1,479 −43% vs ROSSARI
The Sherwin-Williams Company SHW $350.54 $152.59 −56% vs ROSSARI
Givaudan SA GIVN CHF 4,091 CHF 1,618 −60% vs ROSSARI
EMS-CHEMIE HOLDING AG EMSN CHF 839.00 CHF 284.63 −66% vs ROSSARI
Ecolab Inc ECL $308.41 $97.18 −68% vs ROSSARI
Air Products and Chemicals, Inc APD $313.90 $75.33 −76% vs ROSSARI

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rossari Biotech Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rossari Biotech Limited Fair Value". https://www.fairvalue-calculator.com/stock/ROSSARI

Frequently asked questions

Is Rossari Biotech Limited (ROSSARI) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ₹457.92 versus a price of ₹427.15, about +7% upside (fairly valued).
What is the fair value of ROSSARI?
Our model-based fair value for Rossari Biotech Limited is ₹457.92 (as of Nov 14, 2026), built from audited fundamentals. The current price: ₹427.15.
What is the quality score of ROSSARI?
Rossari Biotech Limited has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rossari Biotech Limited (ROSSARI)?
Our model-based price target is the fair value of ₹457.92 (as of Nov 14, 2026) from 16 valuation models. Cautious scenario ₹343.44, optimistic scenario ₹572.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Rossari Biotech Limited stock forecast for 2026?
Our models put fair value at ₹457.92, about +7% upside versus a price of ₹427.15 (fairly valued). Cautious scenario ₹343.44, optimistic scenario ₹572.40. The calculation is refreshed regularly with new filings.
What is the revenue of Rossari Biotech Limited (ROSSARI)?
Rossari Biotech Limited reported trailing-twelve-month revenue of about ₹26.6B (latest available figure, as of Nov 14, 2026).
Does Rossari Biotech Limited pay a dividend?
Rossari Biotech Limited currently shows a dividend yield of 0.12% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Rossari Biotech Limited (ROSSARI)?
Rossari Biotech Limited has a dividend yield of 0.1%.
What is the intrinsic value of Rossari Biotech Limited (ROSSARI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rossari Biotech Limited it is ₹457.92 per share (as of Nov 14, 2026), against a price of ₹427.15. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Rossari Biotech Limited stock overvalued or undervalued in 2026?
As of Nov 14, 2026, ROSSARI trades below its calculated fair value: price ₹427.15, fair value ₹457.92, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ROSSARI?
No. The price is what the market pays today (₹427.15); the fair value is what the company's own numbers justify (₹457.92). For Rossari Biotech Limited the two are ₹30.77 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rossari Biotech Limited worth?
The market values Rossari Biotech Limited at about ₹23.7B (market capitalisation, as of Nov 14, 2026). Per share that is ₹427.15; our models calculate a fair value of ₹457.92 per share.
What do the bullish and bearish scenarios say about ROSSARI?
Our models span a range for Rossari Biotech Limited: cautious scenario ₹343.44, base ₹457.92, optimistic ₹572.40 per share (as of Nov 14, 2026, price ₹427.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ROSSARI?
Rossari Biotech Limited trades at a price-to-earnings ratio of 15.5 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹457.92 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2021 to 2026), reported earnings, FY2026 ex one-offs: 29.7. Other multiples: P/B 1.8, P/S 0.9, EV/EBITDA 8.2.
How solid is the balance sheet of Rossari Biotech Limited (ROSSARI)?
Balance-sheet figures for Rossari Biotech Limited (as of Nov 14, 2026): return on equity 11.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is ROSSARI from its 52-week high?
Rossari Biotech Limited trades at ₹427.15, about 32% below its 52-week high of ₹632.05 and 13% above the low of ₹378.60 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹457.92 is for.
Which stocks are comparable to Rossari Biotech Limited?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rossari Biotech Limited stock attractive at the current price?
The data as of Nov 14, 2026: price ₹427.15, calculated fair value ₹457.92 (+7%), Quality Score 45/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ROSSARI calculated?
We run Rossari Biotech Limited through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹457.92 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Rossari Biotech Limited currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rossari Biotech Limited (ROSSARI)?
The closing price on Nov 16, 2026 was ₹427.15. Our model-based fair value is ₹457.92, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rossari Biotech Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Key figures of Rossari Biotech Limited

How large is the market capitalisation of Rossari Biotech Limited (ROSSARI)?
The market capitalisation of Rossari Biotech Limited is ₹23.7B (≈ $252M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rossari Biotech Limited (ROSSARI)?
The price-to-sales ratio of Rossari Biotech Limited is 0.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rossari Biotech Limited (ROSSARI)?
Earnings per share at Rossari Biotech Limited are ₹27.56 (price ÷ EPS = P/E 15.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Rossari Biotech Limited (ROSSARI)?
The dividend yield of Rossari Biotech Limited is 0.1% (payout 1.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Rossari Biotech Limited (ROSSARI)?
The net margin of Rossari Biotech Limited is 5.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rossari Biotech Limited (ROSSARI)?
The return on equity (ROE) of Rossari Biotech Limited is 11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rossari Biotech Limited (ROSSARI)?
On an EBIT basis the return on assets of Rossari Biotech Limited is 14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rossari Biotech Limited (ROSSARI)?
The operating margin of Rossari Biotech Limited is 8.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rossari Biotech Limited (ROSSARI)?
Revenue at Rossari Biotech Limited is growing 19.0% versus a year earlier (3y avg +13.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Rossari Biotech Limited (ROSSARI)?
Earnings per share at Rossari Biotech Limited are growing 5.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Rossari Biotech Limited (ROSSARI) generate?
The free cash flow of Rossari Biotech Limited is −₹2.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rossari Biotech Limited (ROSSARI) carry?
The net debt of Rossari Biotech Limited is ₹3.4B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Rossari Biotech Limited in the live analysis

One click puts Rossari Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.